Header Logo

Connection

Anthony Rothschild to Depressive Disorder, Major

Back to Details
This is a "connection" page, showing publications Anthony Rothschild has written about Depressive Disorder, Major.
Anthony Rothschild
Connection Strength
12.268
Depressive Disorder, Major
  1. Rothschild AJ. Question: How Should I Switch From One Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) to Another SSRI or SNRI in a Patient With Major Depressive Disorder? J Clin Psychopharmacol. 2024 Sep-Oct 01; 44(5):531-532.
    View in: PubMed
    Score: 0.756
  2. Rothschild AJ. Maintenance treatment of psychotic depression: Is antipsychotic medication needed? Acta Psychiatr Scand. 2024 01; 149(1):3-5.
    View in: PubMed
    Score: 0.724
  3. Rothschild AJ. Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features? J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):359-361.
    View in: PubMed
    Score: 0.608
  4. Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Shelton RC, Macaluso M, Brown K, Lewis D, Gutin A, Jablonski MR, Greden JF. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021 02; 296:113649.
    View in: PubMed
    Score: 0.586
  5. Rothschild AJ. Psychotic depression and suicide. Acta Psychiatr Scand. 2018 04; 137(4):364-365.
    View in: PubMed
    Score: 0.486
  6. Zalpuri I, Rothschild AJ. Does psychosis increase the risk of suicide in patients with major depression? A systematic review. J Affect Disord. 2016 07 01; 198:23-31.
    View in: PubMed
    Score: 0.421
  7. Rothschild AJ. A blood test for depression? J Clin Psychiatry. 2015 Feb; 76(2):e218-9.
    View in: PubMed
    Score: 0.390
  8. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry. 2014 Jan; 55(1):1-10.
    View in: PubMed
    Score: 0.357
  9. Smith EG, Deligiannidis KM, Ulbricht CM, Landolin CS, Patel JK, Rothschild AJ. Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013 Oct; 74(10):966-73.
    View in: PubMed
    Score: 0.356
  10. Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull. 2013 Jul; 39(4):787-96.
    View in: PubMed
    Score: 0.345
  11. Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull. 2009; 42(3):5-20.
    View in: PubMed
    Score: 0.256
  12. Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, Fratoni S, Gabriele M, Kasapinovic S, Meyers BS. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008 Aug; 69(8):1293-6.
    View in: PubMed
    Score: 0.249
  13. Rothschild AJ. The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity. Compr Psychiatry. 2008 Sep-Oct; 49(5):508-13.
    View in: PubMed
    Score: 0.245
  14. Rothschild AJ. Placebo response in psychotic depression. J Clin Psychiatry. 2005 Dec; 66(12):1615; author reply 1615-6.
    View in: PubMed
    Score: 0.207
  15. Butterfield NN, Luzon Rosenblut C, Fava M, Correll CU, Rothschild AJ, Murrough JW, Mathew SJ, Beatch GN, Grayson C, Harden C, Qian J, McIntosh J, Namdari R, Kenney C. Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e2514278.
    View in: PubMed
    Score: 0.198
  16. Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
    View in: PubMed
    Score: 0.197
  17. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004 Aug; 24(4):365-73.
    View in: PubMed
    Score: 0.188
  18. Kim HK, Voineskos AN, Neufeld NH, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Rothschild AJ, Whyte EM, Mulsant BH. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024 Aug; 29(8):2459-2466.
    View in: PubMed
    Score: 0.184
  19. Banerjee S, Wu Y, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Oliver LD, Power JD, Rothschild AJ, Sirey JA, Voineskos AN, Whyte EM, Alexopoulos GS, Flint AJ. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning. Psychol Med. 2024 Apr; 54(6):1142-1151.
    View in: PubMed
    Score: 0.178
  20. Neufeld NH, Oliver LD, Mulsant BH, Alexopoulos GS, Hoptman MJ, Tani H, Marino P, Meyers BS, Rothschild AJ, Whyte EM, Bingham KS, Flint AJ, Voineskos AN. Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features. Mol Psychiatry. 2023 Aug; 28(8):3305-3313.
    View in: PubMed
    Score: 0.174
  21. Bingham KS, Calarco N, Dickie EW, Alexopoulos GS, Butters MA, Meyers BS, Marino P, Neufeld NH, Rothschild AJ, Whyte EM, Mulsant BH, Flint AJ, Voineskos AN. The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression. J Affect Disord. 2023 08 01; 334:317-324.
    View in: PubMed
    Score: 0.173
  22. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003 Apr 15; 53(8):680-90.
    View in: PubMed
    Score: 0.172
  23. Perivolaris A, Ainsworth NJ, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Mulsant BH. Placebo Effect in Randomized Trials of Major Depressive Disorder With Psychotic Features: A Systematic Review and Descriptive Meta-Analysis. J Clin Psychopharmacol. 2022 Sep-Oct 01; 42(5):489-494.
    View in: PubMed
    Score: 0.164
  24. Bingham KS, Neufeld NH, Alexopoulos GS, Marino P, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Meyers BS, Flint AJ. Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. Psychiatry Res. 2022 08; 314:114648.
    View in: PubMed
    Score: 0.162
  25. Parikh SV, Law RA, Hain DT, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Forester BP, Shelton RC, Macaluso M, Cogan ES, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. Psychiatry Res. 2022 02; 308:114354.
    View in: PubMed
    Score: 0.157
  26. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Lerch JP, Flint AJ. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020 07 01; 77(7):674-683.
    View in: PubMed
    Score: 0.142
  27. Forester BP, Parikh SV, Weisenbach S, Ajilore O, Vahia I, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Shelton RC, Macaluso M, Li J, Traxler P, Logan J, Brown L, Dechairo B, Greden JF. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Am J Geriatr Psychiatry. 2020 09; 28(9):933-945.
    View in: PubMed
    Score: 0.141
  28. Shelton RC, Parikh SV, Law RA, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Macaluso M, Hain DT, Aguilar AL, Brown K, Lewis DJ, Jablonski MR, Greden JF. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. Psychiatry Res. 2020 08; 290:113017.
    View in: PubMed
    Score: 0.141
  29. Neufeld NH, Kaczkurkin AN, Sotiras A, Mulsant BH, Dickie EW, Flint AJ, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Mah L, Nierenberg J, Hoptman MJ, Davatzikos C, Satterthwaite TD, Voineskos AN. Structural brain networks in remitted psychotic depression. Neuropsychopharmacology. 2020 06; 45(7):1223-1231.
    View in: PubMed
    Score: 0.139
  30. Dunlop BW, Parikh SV, Rothschild AJ, Thase ME, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Logan J, Traxler P, Li J, Johnson H, Greden JF. Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. BMC Psychiatry. 2019 12 27; 19(1):420.
    View in: PubMed
    Score: 0.137
  31. Thase ME, Parikh SV, Rothschild AJ, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Jablonski MR, Greden JF. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. J Clin Psychiatry. 2019 10 31; 80(6).
    View in: PubMed
    Score: 0.135
  32. Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, Li H, Lasser R, Zorumski CF, Rubinow DR, Paul SM, Jonas J, Doherty JJ, Kanes SJ. Trial of SAGE-217 in Patients with Major Depressive Disorder. N Engl J Med. 2019 09 05; 381(10):903-911.
    View in: PubMed
    Score: 0.134
  33. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019 08 20; 322(7):622-631.
    View in: PubMed
    Score: 0.134
  34. Bingham KS, Whyte EM, Mulsant BH, Rothschild AJ, Rudorfer MV, Marino P, Banerjee S, Butters MA, Alexopoulos GS, Meyers BS, Flint AJ. Health-related quality of life in remitted psychotic depression?. J Affect Disord. 2019 09 01; 256:373-379.
    View in: PubMed
    Score: 0.132
  35. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies. J Psychiatr Res. 2019 07; 114:211-213.
    View in: PubMed
    Score: 0.131
  36. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, Conway CR, Forester BP, Mondimore FM, Shelton RC, Macaluso M, Li J, Brown K, Gilbert A, Burns L, Jablonski MR, Dechairo B. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 04; 111:59-67.
    View in: PubMed
    Score: 0.128
  37. Neufeld NH, Mulsant BH, Dickie EW, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Hoptman MJ, Nazeri A, Downar J, Flint AJ, Voineskos AN. Resting state functional connectivity in patients with remitted psychotic depression: A multi-centre STOP-PD study. EBioMedicine. 2018 Oct; 36:446-453.
    View in: PubMed
    Score: 0.126
  38. Bingham KS, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, Artis AS, Alexopoulos GS, Flint AJ. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018 09; 138(3):267-273.
    View in: PubMed
    Score: 0.123
  39. Bingham KS, Rothschild AJ, Mulsant BH, Whyte EM, Meyers BS, Banerjee S, Szanto K, Flint AJ. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1149-1154.
    View in: PubMed
    Score: 0.117
  40. Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2017 Jun; 25(6):672-679.
    View in: PubMed
    Score: 0.112
  41. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Hum Psychopharmacol. 2016 05; 31(3):252-5.
    View in: PubMed
    Score: 0.106
  42. Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis. Arch Womens Ment Health. 2016 10; 19(5):769-78.
    View in: PubMed
    Score: 0.104
  43. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clin Pharmacokinet. 2015 Nov; 54(11):1161-8.
    View in: PubMed
    Score: 0.103
  44. ?stergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Vermeulen T, Bech P, Meyers BS. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). J Affect Disord. 2016 Jan 15; 190:111-114.
    View in: PubMed
    Score: 0.103
  45. Ulbricht CM, Dumenci L, Rothschild AJ, Lapane KL. Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis. Am J Mens Health. 2018 Jan; 12(1):5-13.
    View in: PubMed
    Score: 0.102
  46. Bingham KS, Whyte EM, Meyers BS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2015 Dec; 23(12):1270-1275.
    View in: PubMed
    Score: 0.101
  47. Gerretsen P, Flint AJ, Whyte EM, Rothschild AJ, Meyers BS, Mulsant BH. Impaired insight into delusions predicts treatment outcome during a randomized controlled trial for Psychotic Depression (STOP-PD study). J Clin Psychiatry. 2015 Apr; 76(4):427-33.
    View in: PubMed
    Score: 0.099
  48. ?stergaard SD, Pedersen CH, Uggerby P, Munk-J?rgensen P, Rothschild AJ, Larsen JI, G?tzsche C, S?ndergaard MG, Bille AG, Bolwig TG, Larsen JK, Bech P. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord. 2015 Mar 01; 173:261-8.
    View in: PubMed
    Score: 0.096
  49. Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Compr Psychiatry. 2014 Jul; 55(5):1069-76.
    View in: PubMed
    Score: 0.091
  50. ?stergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord. 2014 May; 160:68-73.
    View in: PubMed
    Score: 0.090
  51. Kornstein SG, Pedersen RD, Holland PJ, Nemeroff CB, Rothschild AJ, Thase ME, Trivedi MH, Ninan PT, Keller MB. Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. J Clin Psychiatry. 2014 Jan; 75(1):62-8.
    View in: PubMed
    Score: 0.090
  52. Leadholm AK, Rothschild AJ, Nielsen J, Bech P, Ostergaard SD. Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. J Affect Disord. 2014 Mar; 156:119-25.
    View in: PubMed
    Score: 0.090
  53. Deligiannidis KM, Rothschild AJ, Barton BA, Kroll-Desrosiers AR, Meyers BS, Flint AJ, Whyte EM, Mulsant BH. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. J Clin Psychiatry. 2013 Oct; 74(10):1003-9.
    View in: PubMed
    Score: 0.089
  54. Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial. Am J Geriatr Psychiatry. 2014 Apr; 22(4):332-6.
    View in: PubMed
    Score: 0.086
  55. Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. J Nerv Ment Dis. 2013 Apr; 201(4):266-73.
    View in: PubMed
    Score: 0.086
  56. Leadholm AK, Rothschild AJ, Nolen WA, Bech P, Munk-J?rgensen P, Ostergaard SD. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. 2013 Feb 20; 145(2):214-20.
    View in: PubMed
    Score: 0.083
  57. Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, Whyte E, Rothschild AJ, Flint AJ, Meyers BS. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res. 2011 Jul; 45(7):896-901.
    View in: PubMed
    Score: 0.074
  58. Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt AT. Relationships between multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci. 2011; 23(2):198-200.
    View in: PubMed
    Score: 0.073
  59. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M, Trivedi MH. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. J Psychiatr Res. 2011 Jan; 45(1):96-103.
    View in: PubMed
    Score: 0.071
  60. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord. 2010 Nov; 126(3):420-9.
    View in: PubMed
    Score: 0.070
  61. Flint AJ, Peasley-Miklus C, Papademetriou E, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM. Effect of age on the frequency of anxiety disorders in major depression with psychotic features. Am J Geriatr Psychiatry. 2010 May; 18(5):404-12.
    View in: PubMed
    Score: 0.070
  62. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res. 2010 May 15; 177(1-2):177-83.
    View in: PubMed
    Score: 0.070
  63. Schaffer A, Flint AJ, Smith E, Rothschild AJ, Mulsant BH, Szanto K, Peasley-Miklus C, Heo M, Papademetriou E, Meyers BS. Correlates of suicidality among patients with psychotic depression. Suicide Life Threat Behav. 2008 Aug; 38(4):403-14.
    View in: PubMed
    Score: 0.062
  64. Kamara TS, Whyte EM, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Papademetriou E, Mathis ER, Meyers BS. Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features? J Affect Disord. 2009 Jan; 112(1-3):250-5.
    View in: PubMed
    Score: 0.061
  65. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007 Jul; 68(7):1014-23.
    View in: PubMed
    Score: 0.058
  66. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007 Feb; 68(2):194-200.
    View in: PubMed
    Score: 0.056
  67. Meyers BS, English J, Gabriele M, Peasley-Miklus C, Heo M, Flint AJ, Mulsant BH, Rothschild AJ. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility. Biol Psychiatry. 2006 Dec 15; 60(12):1336-42.
    View in: PubMed
    Score: 0.055
  68. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D, Ghosh K, Ball WA, Reines SA, Munjack D, Apter JT, Cunningham L, Kling M, Bari M, Getson A, Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology. 2004 Feb; 29(2):385-92.
    View in: PubMed
    Score: 0.045
  69. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002 Sep 01; 52(5):386-92.
    View in: PubMed
    Score: 0.041
  70. Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013 Jun; 33(3):391-7.
    View in: PubMed
    Score: 0.022
  71. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009 Aug; 66(8):838-47.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.